Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
It exhibits enhanced potency at the GIP receptor (approximately 8.9-fold greater than native GIP) while maintaining clinically relevant but relatively attenuated activation at GLP-1 and glucagon receptors
This means food stays in your stomach longer, keeping you feeling full for a more extended period
This mechanism does not contradict the benefits of GLP-1RAsit complements them by revealing an overlooked trade-off
Understanding this clinical context matters because it sets realistic benchmarks for your own results
Summary: Retatrutide is administered subcutaneously into the abdomen, front thigh, or outer upper arm, following the same injection site principles as licensed GLP-1 class therapies such as semaglutide and tirzepatide
US$ 28.72
US$ 26.64
US$ 26.20
